Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial-Reference-Cited by-全球学者库

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Published:2020-08 Issue:10249 Volume:396 Page:479-488
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Zhu Feng-Cai,Guan Xu-Hua,Li Yu-Hua,Huang Jian-Ying,Jiang Tao,Hou Li-Hua,Li Jing-Xin,Yang Bei-Fang,Wang Ling,Wang Wen-Juan,Wu Shi-Po,Wang Zhao,Wu Xiao-Hong,Xu Jun-Jie,Zhang Zhe,Jia Si-Yue,Wang Bu-Sen,Hu Yi,Liu Jing-Jing,Zhang Jun,Qian Xiao-Ai,Li Qiong,Pan Hong-Xing,Jiang Hu-Dachuan,Deng Peng,Gou Jin-Bo,Wang Xue-Wen,Wang Xing-Huan,Chen Wei

Publisher

Elsevier BV

Subject

General Medicine

Reference21 articles.

1. Rapid COVID-19 vaccine development;Graham;Science,2020

2. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset;Cheng;JAMA Intern Med,2020

3. First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment;Leung;Lancet,2020

4. Developing COVID-19 vaccines at pandemic speed;Lurie;N Engl J Med,2020

5. Developing a vaccine for covid-19;Caddy;BMJ,2020

Cited by 1067 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and limitations of repurposed drugs and vaccines for COVID-19;Journal of Medicine, Surgery, and Public Health;2024-04

2. Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines;Autoimmunity Reviews;2024-03

3. Development of NP-Based Universal Vaccine for Influenza A Viruses;Vaccines;2024-02-02

4. Evaluation of the immunoprotective effects of porcine deltacoronavirus subunit vaccines;Virology;2024-02

5. Next-generation biological vector platforms for in vivo delivery of genome editing agents;Current Opinion in Biotechnology;2024-02